{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Denvir MA"],"funding":["Marie Curie"],"pagination":["24619"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4836296"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6"],"pubmed_abstract":["Future Care Planning (FCP) rarely occurs in patients with heart disease until close to death by which time the potential benefits are lost. We assessed the feasibility, acceptability and tested a design of a randomised trial evaluating the impact of FCP in patients and carers. 50 patients hospitalised with acute heart failure or acute coronary syndrome and with predicted 12 month mortality risk of >20% were randomly allocated to FCP or usual care for 12 weeks upon discharge and then crossed-over for the next 12 weeks. Quality of life, symptoms and anxiety/distress were assessed by questionnaire. Hospitalisation and mortality events were documented for 6 months post-discharge. FCP increased implementation and documentation of key decisions linked to end-of-life care. FCP did not increase an"],"journal":["Scientific reports"],"pubmed_title":["Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease."],"pmcid":["PMC4836296"],"funding_grant_id":["A15867"],"pubmed_authors":["Robertson S","Donald L","Murray SA","Weir CJ","Highet G","Boyd K","Cudmore S","Stephen J","Haga K","Denvir MA","Hogg K"],"additional_accession":[]},"is_claimable":false,"name":"Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease.","description":"Future Care Planning (FCP) rarely occurs in patients with heart disease until close to death by which time the potential benefits are lost. We assessed the feasibility, acceptability and tested a design of a randomised trial evaluating the impact of FCP in patients and carers. 50 patients hospitalised with acute heart failure or acute coronary syndrome and with predicted 12 month mortality risk of >20% were randomly allocated to FCP or usual care for 12 weeks upon discharge and then crossed-over for the next 12 weeks. Quality of life, symptoms and anxiety/distress were assessed by questionnaire. Hospitalisation and mortality events were documented for 6 months post-discharge. FCP increased implementation and documentation of key decisions linked to end-of-life care. FCP did not increase an","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Apr","modification":"2025-04-04T11:41:18.553Z","creation":"2019-03-27T02:11:54Z"},"accession":"S-EPMC4836296","cross_references":{"pubmed":["27090299"],"doi":["10.1038/srep24619"]}}